- Home
- XFOR vs NCSM Comparison
XFOR vs NCSM Comparison
Compare XFOR & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- NCSM
- Stock Information
- Founded
- XFOR 2014
- NCSM 2006
- Country
- XFOR United States
- NCSM United States
- Employees
- XFOR N/A
- NCSM N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- NCSM Oilfield Services/Equipment
- Sector
- XFOR Health Care
- NCSM Energy
- Exchange
- XFOR Nasdaq
- NCSM Nasdaq
- Market Cap
- XFOR 84.3M
- NCSM 76.3M
- IPO Year
- XFOR N/A
- NCSM 2017
- Fundamental
- Price
- XFOR $3.21
- NCSM $48.62
- Analyst Decision
- XFOR Strong Buy
- NCSM
- Analyst Count
- XFOR 3
- NCSM 0
- Target Price
- XFOR $34.17
- NCSM N/A
- AVG Volume (30 Days)
- XFOR 1.5M
- NCSM 19.5K
- Earning Date
- XFOR 11-12-2025
- NCSM 10-29-2025
- Dividend Yield
- XFOR N/A
- NCSM N/A
- EPS Growth
- XFOR N/A
- NCSM N/A
- EPS
- XFOR N/A
- NCSM 4.71
- Revenue
- XFOR $32,774,000.00
- NCSM $175,468,000.00
- Revenue This Year
- XFOR $1,313.84
- NCSM $9.11
- Revenue Next Year
- XFOR N/A
- NCSM $7.13
- P/E Ratio
- XFOR N/A
- NCSM $10.20
- Revenue Growth
- XFOR 5721.31
- NCSM 19.31
- 52 Week Low
- XFOR $1.35
- NCSM $16.81
- 52 Week High
- XFOR $26.83
- NCSM $51.49
- Technical
- Relative Strength Index (RSI)
- XFOR 51.32
- NCSM 68.17
- Support Level
- XFOR $3.08
- NCSM $44.05
- Resistance Level
- XFOR $3.79
- NCSM $51.49
- Average True Range (ATR)
- XFOR 0.40
- NCSM 3.23
- MACD
- XFOR -0.11
- NCSM 0.45
- Stochastic Oscillator
- XFOR 16.92
- NCSM 80.10
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.